🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASH24 #mmsm 9️⃣ Inobrodib (CCS1477) ➡️ ash.confex.com/ash/2024/webpr… ✅new oral compound, inhibitor of conserved bromodomains of p300 and CBP ✅n=48 pts ✅ORR: 75 at best dose level Early results but important to see post BCMA therapy how this compound will do

Learn the latest results of the NCRI AML18 trial for patients with Acute Myeloid Leukaemia with Cardiff ECMC deputy lead Steve Knapper in the oral session 617. #ASH24 NCRI Partnership | Cardiff and Vale University Health Board | ASH

CONGRESS | #ASH24 | PRESENTATION Emma Searle The Christie NHS shares results from the phase I portion of the cAMeLot-1 trial of bleximenib monotherapy in patients with KMT2Ar or NPM1 mutated R/R acute leukemia. The RP2D was determined to be 100 mg BID, with a CR/CRh rate of 33%

Head over to session 613 to meet Anna Castleton (The Christie NHS), who is presenting a poster on the analysis of Brexucabtagene Autoleucel for relapsed/refractory adult acute lymphoblastic leukaemia. #ASH24 Anna Zaiga Castleton | ASH

Could only squeeze into the back of one of the 2 packed overflow rooms to watch Charlotte Pawlyn Charlotte Pawlyn deliver a powerful masterclass in the benefits to understanding and treatment of successive national UK trials in myeloma 👏👏

Sup (ino)bro(dib)! A bromodomain inhibitor inobrodib in combination with pomalidomide. - Short half-life --> BID dosing - Most patients were refractory to pomalidomide (70%) - Interrupted dosing schedule introduced due to thrombocytopenia. - 49% ORR and 75% ORR at the highest

What an experience presenting the first in combination data with Inobrodib Pom and Dex in easily the largest room I’ve ever spoken in! Fantastic to be part of the “into the future” myeloma session to finish off a great #ASH2024. Safe travels home all!

Practice changing update for restarting Tec after a break

bsky.app/profile/dr-emm…

Editorial highlighting very interesting and informative article. Great work nizar jacques bahlis BCMA bispecifics: breaking the chains of resistance ashpublications.org/blood/article/…

SIGN UP: thelimbic.com/uk/haematology… UK haematologists. start your 2025 CPD with our upcoming post-ASH webinar featuring key highlights in myeloma, lymphoma, leukaemia, and MPNs focusing on the impact on clinical practice. Graham jackson Emma Searle Helen Marr anjum khan

Thanks OncoAlert for sharing our work. Podcast discussing this Journal of Clinical Oncology paper with ECMC Network (@ecmc-uk.bsky.social) Natalie Cook 💙, NECTA ONCODOC and CCTG Lesley Seymour has now been published. 👂tinyurl.com/yck9cexh

#ReviewSeries: Villaume and Savona review the current knowledge of inflammaging and aging of the hematopoietic system connecting them with the progression from CHIP to myelodysplastic syndromes. haematologica.org/article/view/h…

In the phase 3 CEPHEUS trial, patients with multiple myeloma were treated with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone, which led to a deeper and more durable increase in minimal residual disease responses Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 nature.com/articles/s4159…

U.S. Food and Drug Administration is expected to decide on linvoseltamab as a treatment for heavily pretreated adults with RRMM by July 10. rarecancernews.com/news/fda-decid… July10 PDUFA date at FDA. Regeneron.

Fascinating results of the 1st published study of HMA/Ven vs. 7+3 for younger AML pts in @BloodJournal. We cannot continue to Tx AML as a 1-size fits all paradigm. Intensive chemo still optimal for favorable-risk. But HMA/Ven may be best in select subgroups even in younger pts 👇

🚨 NEWS 🚨 EU Medicines Agency CHMP recommends marketing authorization approval for linvoseltamab, a BCMA-directed bsAb, for the treatment of RRMM after ≥3 prior therapies, including a PI, an IMiD, and an anti-CD38 mAb, with progression on the last therapy; based on data from phase I/II

What are the latest advancements in menin inhibitors for the treatment of AML? For more information check out our article summarizing presentations from #ASH24 on this topic. 👉 loom.ly/VC3st7s Ghayas Issa Emma Searle Joshua Zeidner MD Amer Zeidan MBBS,MHS ‏عامر زيدان #AMLsm #leusm #MedEd

Proud to finally get this data out. A negative study but very important to make sure our negative studies are published and learned from too. Thanks to my co-authors and all the patients who took part onlinelibrary.wiley.com/share/YV6DJTTE…

AbbVie Pays Up to $1.9 Billion for Trispecific Antibody | Cancer Discovery News | American Association for Cancer Research aacrjournals.org/cdnews/news/25…